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ABSTRACT  
 
Electronic health records hold great promise for clinical and epidemiologic research. 
Undertaking atopic eczema (AE) research using such data is challenging due to its episodic and 
heterogeneous nature. We sought to develop and validate a diagnostic algorithm that identifies 
AE cases based on codes used for electronic records used in the UK Health Improvement 
Network (THIN). We found that at least one of 5 diagnosis codes plus two treatment codes for 
any skin-directed therapy were likely to accurately identify patients with AE. To validate this 
algorithm, a questionnaire was sent to the physicians of 200 randomly selected children and 
adults. The primary outcome, the positive predictive value (PPV) for a physician-confirmed 
diagnosis of AE, was 86% (95%CI 80-91%). Additional criteria increased the PPV up to 95% 
but would miss up to 89% of individuals with physician-confirmed AE. The first and last entered 
diagnosis codes for individuals showed good agreement with the physician-confirmed age at 
onset and last disease activity; the mean difference was 0.8 years (95% CI -0.3,1.9) and -1.3 
years respectively (95%CI -2.5, -0.1).  A combination of diagnostic and prescription codes can 
be used to reliably estimate the diagnosis and duration of AE from the THIN primary care 
electronic health records in the UK.  
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INTRODUCTION 
 
Atopic eczema (AE, synonymous with atopic dermatitis and commonly referred to as eczema) is 
one of the 50 most burdensome diseases worldwide (Vos et al., 2012, Weidinger and Novak, 
2016). Therefore there is great interest in understanding its causes, natural history and potential 
associations with comorbid conditions. Yet most studies rely on highly selected specialty clinic 
populations, cross-sectional studies, or self-reported data, and are prone to bias and limited 
generalizability (Asher et al., 1995), (Deckert et al., 2014). Representative population-level data 
with validated diagnoses and longitudinal follow up are needed.  
 
Electronic health data from primary care practices in the UK present an opportunity to directly 
address many of the unanswered questions about long-term outcomes in AE in particular. They 
are representative of the general population, include relatively long term follow up of both 
children and adults, and are appropriate for the study of AE since 97% of patients are managed 
by general practitioners in the UK (Emerson et al., 1998, Schofield JK, 2009). However, these 
data were created for administrative and clinical purposes, not designed specifically for research, 
and it is therefore critically important that the validity of AE diagnoses in these data sources is 
understood (Manuel et al., 2010). Because AE is a heterogeneous and episodic condition with 
non-specific terminology, there exists high potential for misclassification of diagnosis and 
duration of disease. There is no single diagnostic test for AE and it can be challenging to 
diagnose in population-based studies due to its variability in morphology, distribution and 
periodicity. The diagnosis relies on clinical judgment based on a combination of history and 
physical examination. Previous studies using UK primary care data to identify patients with AE 
report wide variations in prevalence from 0-38% based on the coding algorithm used (Anandan 
et al., 2009, Carey et al., 2003, McKeever et al., 2001, cKeever et al., 2002, 2004, Punekar and 
Sheikh, 2009, Simpson et al., 2002, Simpson et al., 2009). Moreover, there is some evidence that 
chronic diseases, such as AE, may be more poorly recorded over time in UK general practice 
data, as general practitioners are not required to enter codes on each occasion for chronic 
conditions (Jordan et al., 2004, Khan et al., 2010).  
  
This study aimed to enhance identification of patients with AE within electronic health records. 
The objectives were to develop and validate a diagnostic algorithm for AE that identifies cases 
based on codes, and secondarily, to examine the agreement between physician report and codes 
for AE disease onset, duration and severity.  
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RESULTS  
 
Algorithm development 
A list of potential AE diagnosis and treatment codes were developed by employing a keyword 
search and examining affiliated codes (Supplemental Table 1), and the five most common and 
specific codes for AE were chosen to identify those likely to have AE:  m111.00 atopic 
dermatitis/eczema, m1120.0 infantile eczema, m113.00 flexural eczema, m11400 
allergic/intrinsic eczema, m12z100 eczema NOS. When we examined the frequency of medical 
codes among individual patients, we found that including 32 codes likely to be related to AE 
rather than only the 5 most common codes only slightly increased the number of individuals 
identified, but including up to 74 possible AE codes nearly doubled the number of individuals 
identified (Table 1). The distribution of some codes varied between children and adults; for 
example, m1120.0/infantile eczema was more commonly used in children.  
 
Despite the chronicity of AE, any of the 5 most common diagnosis codes were rarely repeated in 
the database; overall, patients had a mean of 1.2 (standard deviation 0.5) codes during 5.6 years 
(standard deviation 8.0) of follow-up. Because AE is by definition a chronic condition, it was 
important to include more than one code in our algorithm, but requiring individuals to have two 
or more diagnosis codes would exclude >80% of the potential AE population. Therefore, the 
distribution of treatment codes was also examined. In the UK, medical record codes and 
treatment codes can be entered independently (i.e. a prescription code does not require an 
associated diagnostic code). Prescriptions, including emollient preparations, are available 
through the National Health Service, so we examined prescription codes for all potential relevant 
therapies including topical emollients, topical steroids, topical calcineurin inhibitors, topical anti-
infective treatments, and systemic immunomodulatory medications (including methotrexate, 
azathioprine, mycophenolate, cyclosporine, or biologics) based on British National Formulary 
groupings, and phototherapy codes (British National Formulary, 2016; Supplemental Table 2). 
Since prescriptions are free of charge for children only, we stratified our analyses by age (i.e. 
children under 18 versus adults). We also specifically examined the use of topical steroids and 
topical calcineurin inhibitors (which are likely to be more specific for AE). To ensure we 
captured patients with chronic AE in our algorithm, we chose to include patients with at least one 
of the 5 medical codes frequently used for AE as listed above and at least 2 treatment codes for 
any AE-related therapy on separate dates (at any time point relative to the AE diagnosis, since 
symptoms may precede the actual diagnosis).   
 
Physician Survey  
To validate the algorithm for AE, we surveyed the physicians of a random sample of 100 
children (< 18 years of age) and 100 adults (Figure 1). The response rate was 97% overall (96% 
for adults and 97% for children), and there was no significant difference in response rate by age 
or sex. The algorithm for identifying patients with AE performed well and there were no 
significant differences in codes between those with and without physician confirmed AE (Table 
2). The positive predictive value (PPV) for a single diagnostic code and at least two treatment 
codes was 86% overall (95%CI 80-91%); and was higher among children (90%) than adults 
(82%), though this difference was not statistically significant (Pearson chi2=2.76, p=0.097).  
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When we examined whether the use of more stringent criteria would improve the prediction of 
physician-confirmed AE, we found that adding additional criteria to the algorithm had the 
potential to increase the PPV, but would result in smaller numbers of individuals being detected 
(Table 3). For example, requiring two AE codes would increase the PPV to 91%, but would only 
detect 83/163 or 51% of those with physician-confirmed AE. Similarly, requiring a dermatology 
consult code in addition to the AE and prescription codes would increase the PPV to 95%, but 
would only detect 18/163 or 11% of those with physician-confirmed AE. Requiring the 
prescriptions to be for medications more specific to AE (i.e. topical steroids or calcineurin 
inhibitors) did not significantly change the PPV.  
 
The average age of onset and oldest age of disease activity requiring physician contact estimated 
using codes from the database were similar to what physicians reported (Table 4). The mean 
estimated age at onset using the first diagnosis code or first treatment code were both slightly 
younger than the physician estimate (mean difference 0.8 years, 95%CI -0.3 to 1.9 and 0.4  
years, 95% CI -0.8 to 1.7 years, respectively), and 76% of estimates were within one year of each 
other. The mean estimated age at last date of AE activity using the last diagnosis code or last 
treatment code were both older than the physician estimate (mean difference -1.3, 95%CI -2.5 to 
-0.1, and -3.9 years, 95%CI -5.3 to -2.4 years, respectively), and 79% of estimates within five 
years of each other. Bland Altman plots for all estimates are shown Supplemental Figure 4. 
When we stratified these estimates by age comparing children under age 18 to adults we found 
similar results (Supplemental Table 4).  
 
In our sample, 48 patients were reported by the physician to have had symptoms in the year prior 
to their last visit; 27 (56%) of whom were assessed as having mild disease and 19 (40%) of who 
were assessed as having moderate disease based on the severity descriptions in the National 
Institute for Health and Care Excellence (NICE) guidelines. Patients with moderate disease had 
more treatment codes during that year than patients with mild disease (median 5 versus 2, p-
value for two-sample Wilcoxon rank sum test =0.887). None were reported to have severe 
disease, limiting our ability to draw any conclusions about the validity of medical record codes to 
predict disease severity.  
 
Finally, we assessed whether physicians would be able to adequately respond to the UK Working 
Party criteria (originally designed for in-person assessment), enabling us to compare a set of 
well-validated criteria for use in large epidemiologic studies to our outcomes in routinely 
collected electronic health data. For each question, we gave physicians the option of choosing 
‘don’t know’. The high number of uncertain responses resulted in poor ability to discriminate 
between those with and without AE (Supplemental Table 5). We found that only 52 (32%) of 
those with physician-confirmed AE in our sample met the criteria (an itchy skin condition plus at 
least 3 of history of flexural involvement, history of asthma/hay fever, history of generalized dry 
skin, onset of rash under age 2, and visible flexural dermatitis).  
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DISCUSSION  
 
Interpretation of main findings 
Patients with AE were accurately identified if they had at least one AE diagnostic code and at 
least two prescription codes for AE-related treatments in a large electronic medical record 
database representative of the general population in the UK. The positive predictive value, or 
probability that individuals identified by our algorithm truly have the disease as determined by 
their doctor, was 86%, which is similar to the PPV of coding algorithms for other chronic 
diseases in routinely collected data (Khanet al., 2010). The PPV was higher in children, but the 
algorithm still performed well to identify adults with AE.  
 
This study indicates that the types, number, and frequency of codes used to identify AE patients 
in routinely collected data are important because small differences have the potential to cause 
substantial misclassification. After examining the distribution of all of codes potentially related 
to AE, we chose to use the 5 most common AE codes in addition to treatment codes for the 
primary algorithm. As shown in Table 1, expanding the definition from 5 to 32 codes (likely 
related to AE but rarely used) would have only increased the proportion of the population 
identified from 13 to 14%, so we opted for the more parsimonious algorithm. In contrast, using a 
single code to define AE, for example AD/Eczema (M111.00), would identify far fewer 
individuals (only 6% of the population). Although it was impractical and prohibitively costly to 
sample enough physicians to calculate the sensitivity, specificity and predictive value of each of 
these variations, we present the proportion of patients identified by each set of codes to illustrate 
the potential magnitude of misclassification. We were able to calculate post-hoc changes in the 
PPV caused by adding criteria to our algorithm. Inclusion of a second diagnosis code, allergy 
code, or consult code all increased the PPV, but would identify far fewer patients. The ideal 
balance between these factors depends on the research question. For example, an algorithm with 
a very high PPV that captures only a fraction of those with disease may be acceptable for a case-
control study. On the other hand, the ideal algorithm for a prevalence study would aim to assess 
the total population burden accurately and may include more mild or marginal cases.  
 
Because AE is a chronic condition, we explored the possibility of using codes from more than 
one time point to identify patients. In the UK, providers are not required to re-enter codes for 
chronic conditions, and only 36% of individuals had more than 1 AE diagnosis code. Treatment 
codes, which can be entered independently from diagnostic codes, were used more frequently, 
and were therefore included in the algorithm. When selecting the treatments, we opted for an 
inclusive approach and used all potential AE-related treatments, even emollients, as listed under 
British National Formulary categories. This approach may include treatments not specifically for 
AE, so we examined the performance of a more limited definition of treatments (only topical 
steroids or topical calcineurin inhibitors), and found it did not change the PPV but would identify 
4-18% fewer patients (Table 3). Of note, 22% of individuals with one of the 5 most common 
medical codes never received any treatment codes. Our algorithm excluded these patients, some 
of whom may have had mild untreated disease.  
 
Because we randomly selected individuals with AE diagnoses at any time point, only a fraction 
had disease activity during the year prior to their last visit, resulting in too few numbers to 
meaningfully assess the validity of codes relative to disease severity. Additional research is 
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necessary to validate whether codes can be used to ascertain severity and disease flares in 
routinely collected data.  
 
Comparability to other studies 
Three other studies attempted to validate routinely collected data for identifying individuals with 
AE. Two examined the use of medications alone and found they had poor discriminatory power 
to identify patients with AE in the Netherlands and Sweden (Mulder et al., 2016, Ortqvist et al., 
2013). The distribution of treatment codes in our data, as shown in Table 1, also suggested that 
the were not likely to selectively identify patients with AD, which is why we designed our 
algorithm to incorporate both diagnosis and treatment codes as described above. The third 
compared ICD-9 codes from a tertiary care population in the US with Hanifin & Rajka and UK 
Working Party (UKWP) criteria found in the medical record and found poor overlap (Hsu et al., 
2016), possibly due to the lack of standardized recording of specific diagnostic features in the 
medical record. We assessed whether it was possible to compare our results to the UK Working 
Party diagnostic criteria, which have been used for epidemiological studies in multiple 
international settings, but were developed for in-person assessment (Brenninkmeijer et al., 2008, 
Williams et al., 1994). Because physicians responded, “don’t know” to so many of the UK 
Working Party questions in our survey, we were unable to make meaningful comparisons.  We 
hypothesize the high rates of uncertainty were because there was not enough data in the medical 
record to enable physicians to answer all of the required questions, and therefore caution against 
using these as a gold standard from medical record review when they were not systematically 
assessed. It is also possible that those deemed to have AE by their physician simply would not 
fulfill the criteria if they had been ascertained fully, and further specially designed studies are 
needed to test this notion. 
 
Strengths and weaknesses  
Strengths of our study include the use of diagnosis and treatment codes, stratified sampling 
among children and adults, a large representative database with longitudinal follow up, and 
physician-confirmation of disease as the gold standard. We sampled general practice physicians 
rather than dermatologists because 97% of patients with AE are managed by general 
practitioners in the UK, and sampling specialists would have limited the generalizability of the 
results (Emersonet al., 1998, Schofield JK, 2009). 
 
Ideally, patients would have been assessed in person to confirm their diagnoses. Because this 
was not possible through the Additional Information Services in THIN, we queried their 
physicians instead. The physicians were asked to assess the patient based on their recall and 
review of the medical record. This approach was chosen over a medical record review because it 
allowed for direct assessment as to whether the physician really believed the patient had AE 
(regardless of coding). 
 
Our results are only directly generalizable to The Health Improvement Network, though the 
algorithm is likely to perform similarly in the other UK primary care databases which have 
substantial overlap (the Clinical Practice Research Datalink https://www.cprd.com/, and other 
UK primary care data sources including QResearch http://www.qresearch.org/). Validation 
studies are inherently context-specific, and the PPV of our algorithm may vary in settings where 
the prevalence of AE and data structure differ. For example, we found that adding a dermatology 
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consult code to our baseline algorithm increased the PPV to 90% (95%CI 74-100%, Table 3), 
however it only identified 11% of the patients with confirmed eczema because very few patients 
are referred to specialists in the UK. In the USA, where the proportion of patients who are 
referred to a specialist is higher (it is estimated 43% of pediatric AE visits were to generalists 
between 1997 and 2004, Horii et al., 2007), adding a dermatology consult code to the baseline 
algorithm is likely to identify a higher proportion of patients with confirmed AE. If our algorithm 
were used in settings where patients do not receive prescriptions for emollients or other topical 
preparations or anti-infective treatments, its performance may be more comparable to the first 2 
alternative algorithms listed in Table 3 that are based on the use of topical steroids and 
calcineurin inhibitors alone. We emphasize the importance of carefully examining the 
distribution and types of codes before undertaking a study using electronic medical record data, 
and we present the distribution of categories of codes in Table 1 so that researchers can evaluate 
how applicable our results may be to their data.  
 
Implications for future research 
Validation studies that ensure patients are accurately identified are a high priority to enable the 
use of increasingly available and robust sources of routinely collected electronic health data (De 
Coster et al., 2006), but have not been widely employed in the AE literature to date. This study 
showed that AE patients can be accurately identified in the UK Health Improvement Network, 
and that changes in the number, type or frequency of codes used could result in large differences 
in the number of patients identified. Additional work is necessary to determine the PPV of our 
algorithm in other contexts. We highlight factors to consider when examining the frequency and 
distribution of diagnostic and treatment codes in any electronic medical record database, which 
are important for researchers to avoid misclassification bias. Efforts are underway to determine 
how AE patients have been identified in published studies using electronic health data (Dizon et 
al., 2016), and we encourage the research community to work towards developing standards for 
methodology and reporting to improve comparability of studies and advance our understanding 
of AE.  
 
METHODS 
 
Study design  
Our study consisted of two parts: a longitudinal cohort study to develop a diagnostic algorithm, 
and a physician survey to validate it. We followed guidelines for reporting of validation studies 
and reporting of studies conducted using observational routinely collected health data 
(Benchimol et al., 2011, Benchimol et al., 2016). 
 
Participants/Data source 
The Health Improvement Network (THIN) is a database comprising the electronic health records 
of people registered with participating general practices. THIN is broadly representative of the 
general UK population in terms of age, sex, ethnicity, and geography and is one of three major 
UK primary care databases (Shephard et al., 2011). We chose this data source because it is one 
of the world’s largest sources of anonymized longitudinal data from primary care practices with 
over 85 million patient-years of follow up, and because we had institutional access and 
experience using the data (Margolis et al., 2007, Margolis et al., 2008, Ogdie et al., 2015, 
Seminara et al., 2011). Previous validation studies have shown that the recording is highly 
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accurate and nearly complete, and THIN has been used to study multiple chronic conditions. 
Participating practices are remunerated for recording data on clinical diagnoses, test results, 
prescriptions, and referral data via the Read/OXMIS (Oxford Medical Information System) 
coding framework, which is based on the International Classification of Diseases (ICD) coding 
system. The raw data are updated monthly and undergo extensive quality control and validity 
checks by a centralized research team before release. Practices may choose to participate in the 
Additional Information Services Program, which administers surveys to consenting physician 
practices. Approximately 60% of all THIN practices actively participated in this program when 
our survey was administered in October 2015.  
 
Algorithm development 
A list of potential AE diagnosis and treatment codes were developed by employing a keyword 
search and examining affiliated codes (Supplemental Table 1). The distribution of codes was 
examined, and in consultation with a panel of experts on AE epidemiology and use of routinely 
collected data (HCW, DM, LM, SML, KA) a parsimonious algorithm was developed to identify 
patients most likely to have AE.  
 
Physician Survey 
The survey was sent to the physicians of a random sample of 100 children (<18 years of age) and 
100 adults with acceptable records who were alive and currently enrolled in practices 
participating in the Additional Information Services (Figure 1). The primary outcome was the 
positive predictive value (PPV), or probability that subjects identified by the algorithm truly have 
the disease, as this measure is the most relevant for avoiding misclassification bias in subsequent 
studies of AE (Choi, 1992). Assuming a physician response rate of 90% (based on prior studies 
using physician confirmation of chronic disease in routinely collected data (Khanet al., 2010, 
Seminaraet al., 2011)), a sample of 200 patients should have enabled us to obtain a 95% 
confidence interval of 0.85-0.94 around an a priori estimated PPV of 0.90. Given funding 
constraints we chose to sample only patients with codes suggestive of AE. Sampling additional 
subjects without AE codes would have enabled us to also calculate sensitivity and specificity of 
the algorithm.  
 
A standardized letter was sent to each practice requesting completion of a 1-page survey 
(supplemental Figures 2-3), and physicians received monthly reminders for completion and 
compensation for their time. If the diagnosis of AE was confirmed, we then asked the physician 
to (1) provide a global assessment of average AE severity over the past 12 months, (2) confirm 
the age at AE onset, and (3) confirm whether the patient still has active AE or whether the 
patient’s AE is in remission. Although many eczema-specific severity scales have been 
developed and validated for assessment of patient outcomes in clinical trials, few are designed to 
address long-term severity (Schmitt et al., 2007). Therefore, to asses severity, we used 
descriptions of mild, moderate, and severe disease from the UK National Institute for Health and 
Care Excellence (NICE) guidelines for management of eczema (NICE, 2007). Finally, to 
determine whether our results could be compared to another widely used definition of AE in 
large epidemiologic studies, the survey included the UK Working Party refinement of Hanifin 
and Rajka’s diagnostic criteria questions (Brenninkmeijeret al., 2008, Williamset al., 1994). 
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AE is a clinical diagnosis, and biopsy and laboratory tests are non-specific, therefore we relied 
on the physician’s confirmation of the diagnosis as the gold standard. This approach is consistent 
with other validation studies of chronic conditions in medical record databases in UK primary 
care databases (Ogdie et al., 2014, Seminaraet al., 2011, Soriano et al., 2001). Physicians were 
asked to fill out the survey based on their knowledge of the patient and review of his or her 
medical record.  
 
Analysis 
For the 200 patients whose physicians were surveyed, differences in codes between those with 
and without physician-confirmed AE were examined and the PPV of our algorithm for 
identifying AE patients was calculated. The PPVs of alternative algorithms with additional 
criteria for identifying patients with AE were also calculated. Next, the age of disease onset and 
“remission” reported in the physician survey were compared to dates calculated from the 
database using the first and last AE diagnosis and prescription codes. Agreement was assessed 
descriptively using Bland Altman plots (Bland and Altman, 1986). All analyses were stratified 
by age (i.e. children under 18 vs adults). Analyses were performed using Stata (Version 14, Stata 
Corporation, College Station, Tx). 
 
Ethics 
Approval was obtained from the Scientific Research Council of THIN and the University of 
Pennsylvania IRB.   
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Table 1. Distribution of codes in the entire THIN database 
  
Total Children (ages 0-17) 
Adults 
(ages 18+) 
  N = 9,775,618 N = 1,404,158 N = 8,371,460 
Diagnosis codes Proportion of individuals 
Atopic Dermatitis/ Eczema M111.00  6% 13% 5% 
Infantile Eczema M112.00  1% 7% 0% 
Flexural Eczema M113.00  1% 2% 0% 
Allergic/Intrinsic Eczema M114.00  0% 0% 0% 
Eczema NOS M12z100 6% 8% 6% 
One or more of the 5 codes listed above 13% 23% 11% 
Two or more of the 5 codes listed above  4% 10% 4% 
  
One or more of 32 likely eczema codes* 14% 25% 13% 
One or more of 74 possible eczema codes* 29% 47% 26% 
    
Prescription codes    
One or more prescription for any AD-related therapy** 45% 57% 42% 
One or more prescription for a topical steroid or calcineurin inhibitor** 39% 42% 38% 
One or more prescription for an AD-related systemic treatment ** 1% 0% 1% 
    
Other codes    
One or more exclusionary condition*** 7% 3% 8% 
One or more dermatology consult code 4% 2% 5% 
One or more biopsy or patch testing code 1% 0% 1% 
Notes: Ages as of Jan 2013; note that among adults, codes may have occurred before age 18. *See Supplemental Table 1. **Includes 
topical skin preparations, topical steroids, topical calcineurin inhibitors, topical anti-infective treatments, and systemic treatments 
(including methotrexate, azathioprine, mycophenolate, cyclosporine, biologics or phototherapy); see supplemental Table 2. ***See 
Supplemental Table 3.  
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Table 2. Survey sample characteristics 
Survey responses Total*  Confirmed 
eczema* 
No eczema* 
Chi2 or 
Fisher’s 
p-value 
  
200 163 (81.5%) 26 (13%)   
Diagnosis codes       
Atopic Dermatitis/ Eczema M111.00  116 (58%) 98 (60%) 13 (50%) 0.330 
Infantile Eczema M112.00  30 (15%) 24 (15%) 4 (15%) 0.930 
Flexural Eczema M113.00  16 (8%) 13 (8%) 2 (8%) 0.960 
Allergic/Intrinsic Eczema M114.00  3 (2%) 3 (2%) 0 (0%) 0.486 
Eczema NOS M12z100 86 (43%) 73 (45%) 9 (34%) 0.331 
Mean number (SD) of the 5 eczema codes listed above  1.3 (0.5) 1.3 (0.6) 1.1 (0.3) 0.051 
Mean number (SD) of 32 likely eczema codes**  2.6 (2.9) 2.8 (3.1) 1.7 (1.2) 0.070 
Mean number (SD) of 74 possible eczema codes** 4.0 (3.8) 4.1 (3.9) 3.2 (3.3) 0.271 
Prescription codes         
Mean number (SD) of prescriptions for any AD-related therapy*** 16.3 (24.5) 17.5 (26) 11.1 (15.0) 0.226 
Mean number (SD) of topical steroid or calcineurin inhibitor prescriptions*** 9 (15) 6.6 (8.9) 6.5 (7.9) 0.953 
Mean number (SD) of AD-related systemic treatment codes*** 0.4 (5.8) 0.5 (6.4) 0 (0) 0.691 
Other         
Mean number (SD) of exclusionary diagnostic codes^ 0.4 (1.7) 0.3 (0.7) 0.5 (1.6) 0.281 
Total (%) with at least one exclusionary condition^ 29 (15%) 25 (15.3%) 3 (11.5%)   
Mean number (SD) of diagnostic procedure (biopsy or patch testing) codes^ 0 0 0 N/A 
Mean number (SD) of dermatology consultation codes^ 0.2 (1.1) 0.3 (1.6) 0.0 (0.2) 0.308 
Total (%) with at least one dermatology consult code 19 (10%) 18 (11%) 1 (4%)   
History of atopy, N (%)^^ 64 (39%) 56 (41%) 6 (24%) 0.110 
Male N (%) 100 (50%) 86 (53%) 9 (35%) 0.086 
Notes: *Columns do not sum to 200 because of missing values (7 unreturned surveys and 4 returned surveys missing a response to the eczema question). **See 
Supplemental Table 1. ***Includes topical skin preparations, topical steroids, topical calcineurin inhibitors, topical anti-infective treatments, and AD-related 
systemic treatments (including methotrexate, azathioprine, mycophenolate, cyclosporine, biologics or phototherapy); see supplemental Table 2.  ^See 
supplemental Table 3. ^^Per physician response on survey; defined as a history of "other atopic disease (e.g. asthma or allergic rhinitis) for adults OR a family 
history of atopic disease in a first degree relative if aged under 4 years" 
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Table 3. Positive Predictive Value of Coding Algorithms 
  
  
  All 
Children  
(ages 0-17) 
Adults 
(ages 18+) 
Baseline algorithm True 
Positive
/ All 
Positive 
% of 
patients 
with 
confirmed 
eczema 
identified 
PPV 
(%) 
95%CI PPV 
(%) 
95%CI PPV 
(%) 
95%CI 
One of 5 eczema codes + at least 2 treatment codes on separate dates 
(survey selection criteria)  163/189 N/A 86% (80-91%) 90% (83-96%) 82% (73-89%) 
Alternative algorithms*                 
Baseline algorithm; at least one treatment is a topical steroid/TCI code 157/183 96% 86% (80-91%) 90% (81-95%) 82% (73-89%) 
Baseline algorithm; at least two treatments are topical steroid/TCI codes 133/153 82% 87% (81-92%) 91% (82-97%) 84% (74-91%) 
Baseline algorithm; at least one treatment is a topical steroid/TCI code 
either 3 months prior or up to 1 year after the eczema code  81/92 50% 88% (80-94%) 92% (80-98%) 84% (70-94%) 
Baseline algorithm + an additional eczema code (2 eczema codes total)  83/91 51% 91% (83-96%) 94% (82-99%) 88% (74-96%) 
Baseline algorithm + an additional eczema code (2 eczema codes total); at 
least one treatment is a topical steroid/TCI code 82/90 50% 91% (83-96%) 94% (83-99%) 88% (74-96%) 
Baseline algorithm + an additional eczema code (2 eczema codes total); at 
least two treatments are topical steroid/TCI code 133/153 82% 87% (81%-92%) 91% (82%-97%) 84% (74%-91%) 
Baseline algorithm + no exclusionary condition code 138/161 85% 86% (79-91%) 89% (81-95%) 82% (71-90%) 
Baseline algorithm + asthma or rhinitis code 52/56 32% 93% (83-98%) 95% (76-100%) 91% (77-98%) 
Baseline algorithm + dermatology consult code 18/19 11% 95% (74-100%) 100% (54-100%) 92% (64-100%) 
Notes: *See Supplemental Tables 2 and 3 for lists of codes. TCI= topical calcineurin inhibitor 
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Table 4.  Age at diagnosis or at last disease activity requiring contact with the physician  
  
Distribution of estimates 
by source 
Difference between 
physician estimate from 
survey and database 
  Mean 95% CI Mean 95% CI 
Age in years at diagnosis (N=160)         
Physician survey 17.9 (14.3, 21.4) N/A N/A 
Database         
First diagnosis code* 17.1 (13.5, 20.6) 0.8 (-0.3, 1.9) 
First prescription for any eczema treatment** 17.4 (13.9, 21.0) 0.4 (-0.8, 1.7) 
          
If no symptoms in the year prior to the last visit date, age at last disease activity 
(N=53)          
Physician survey 20.7 (14.3, 27.2) N/A N/A 
Database     
    
Last diagnosis code* 22.0 (15.6, 28.5) -1.3 (-2.5, -0.1) 
Last prescription for any eczema treatment** 24.6 (14.3, 27.2) -3.9 (-5.3, -2.4) 
Notes: *Any of the 5 most commonly used codes (Atopic Dermatitis/ Eczema M111.00, Infantile Eczema M112.00, Flexural Eczema 
M113.00, Allergic/Intrinsic Eczema M114.00, Eczema NOS M12z100). **See Supplemental Table 2.  
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FIGURE LEGENDS 
 
Figure 1. Flow chart showing the sampling of patients from THIN and resulting classification 
 
Notes: *Any of the 5 most commonly used READ codes (Atopic Dermatitis/ Eczema M111.00, Infantile Eczema M112.00, Flexural 
Eczema M113.00, Allergic/Intrinsic Eczema M114.00, or Eczema NOS M12z100). **Any code for topical emollients, topical 
steroids, topical calcineurin inhibitors, topical anti-infective treatments, systemic immunomodulatory medications (including 
methotrexate, azathioprine, mycophenolate, cyclosporine, or biologics) or phototherapy on separate days; see Supplemental Table 2).  
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